Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanning.

J A Carrasquillo1, M Whatley, V Dyer

  • 1Nuclear Medicine Department, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892-1180, USA.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|September 6, 2001
PubMed
Summary

Alendronate does not interfere with bone scans. This study found that alendronate (a bisphosphonate) did not affect the uptake of technetium-99m-methylene diphosphonate (99mTc-MDP) in bone metastases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First-in-human phase 0 study of <sup>111</sup>In-CHX-A"-DTPA trastuzumab for HER2 tumor imaging.

Journal of translational science·2019
Same author

ANG1005 for breast cancer brain metastases: correlation between <sup>18</sup>F-FLT-PET after first cycle and MRI in response assessment.

Breast cancer research and treatment·2016
Same author

Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer.

International journal of cancer·2016
Same author

Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responses.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2015
Same author

A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib.

United European gastroenterology journal·2015
Same author

Angiogenesis in spontaneous tumors and implications for comparative tumor biology.

TheScientificWorldJournal·2014

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Pharmacology

Background:

  • Etidronate interferes with bone scans, but other bisphosphonates may not.
  • Bisphosphonates are used to treat bone metastases.

Purpose of the Study:

  • To determine if alendronate interferes with 99mTc-MDP bone scans.
  • To assess the effect of alendronate on tracer uptake in bone metastases.

Main Methods:

  • Prospective study of 9 patients with hormone-refractory prostate cancer.
  • Quantitative whole-body bone scanning with 99mTc-MDP before and after alendronate administration.
  • Region-of-interest analysis to determine radioactivity in bone metastases.

Main Results:

  • Initial scans post-alendronate showed <6% increase in whole-body retention of 99mTc-MDP.

Related Experiment Videos

  • No significant difference in tracer activity in bone lesions between baseline and initial post-alendronate scans.
  • Delayed scans showed similar or higher tracer accumulation compared to baseline.

    • Conclusions:

    • Alendronate does not competitively inhibit 99mTc-MDP uptake in the skeleton or tumor metastases.
    • Alendronate use before bone scanning is unlikely to decrease lesion detection or show falsely low activity at metastatic sites.